Wiley Announces Third Quarter FY2016 Conference Call Schedule

HOBOKEN, N.J.--(BUSINESS WIRE)-- John Wiley & Sons, Inc. (NYSE:JWa and JWb), a global provider of knowledge and knowledge-enabled services that improve outcomes in research, professional practice, and education will release its third quarter results prior to market open on Tuesday, March 8, 2016. The Company has scheduled a conference call beginning at 10 a.m. EST that day to discuss the results.

• The live audio webcast and presentation slides will be available at www.wiley.com under Investor Relations, Events and Presentations, or http://www.wiley.com/WileyCDA/Section/id-370238.html. An archive of the webcast will be available on www.wiley.com under Investor Relations for a period of up to one year.
• U.S. and Canada participants can also access the conference call by dialing (888) 364-3108 ten minutes prior to start time and entering the participant code 8846731#. International callers can dial (719) 325-2354 and enter the participant code 8846731#.

About Wiley

Wiley is a global provider of knowledge and knowledge-enabled services that improve outcomes in areas of research, professional practice, and education. Through the Research segment, the Company provides digital and print scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising. The Professional Development segment provides digital and print books, online assessment and training services, and test prep and certification. In Education, Wiley provides education solutions including online program management services for higher education institutions and course management tools for instructors and students, as well as print and digital content.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160301005035/en/

John Wiley & Sons
Brian Campbell, 201-748-6874
Investor Relations
[email protected]

Source: John Wiley & Sons, Inc.

You May Also Be Interested In

• Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage
• Solana Price Prediction Turns Explosive as SOL Rockets 26% and Pepeto Becomes the Entry Everyone Wants
• BNB Price Prediction: BNB Chain Strength Creates a Stronger Setup for MemeToro’s AI Launchpad